
## **Prescription Drug Affordability Boards (PDABs) 101**

Independent state bodies created by state legislation, comprised of experts in healthcare economics, policy, and medicine, tasked with addressing patient affordability challenges and rising drug costs.

# Nine states currently have active PDABs that focus on conducting affordability reviews and setting payment limits for "high cost" drugs



## Affordability reviews

**Drug selection:** Involves consideration of numerous factors, including drug pricing (e.g., WAC of \$30,000/yr; WAC increases of 10% or more), patient out-of-pocket cost, and state financial burden.

Affordability review process: PDAB reviews the cost of prescription drugs to assess affordability for patients and insurers, with the support of advisory boards and input from advocacy groups, payers, industry, and the public.

Less impact

### **Level of impact of PDAB actions**

**Greater impact** 

#### **Conduct affordability reviews**

Provide recommendations to state legislatures on policy interventions to reduce prescription drug spending.

ME, NJ, OR

### **Medicaid negotiation**

Engage in negotiations for Medicaid supplemental rebates with pharmaceutical companies.

MA, NY

NEW!

**Set UPLs** Conduct affordability reviews and set reimbursement limits on what payers within a state will pay for selected drugs. **CO, MD, MN, WA** 

## Colorado, Maryland, Washington, and Oregon have selected drugs for affordability review



#### Colorado

"Unaffordable" drugs:

 Immunology (Enbrel, Cosentyx, Stelara)

## Drugs deemed not to pose an affordability challenge:

- · HIV (Genvoya)
- · Rare Disease (Trikafta)



## Maryland

"Unaffordable" drugs:

· Immunology (Farxiga, Jardiance)

#### Drugs under review:

- · Immunology (Skyrizi)
- · Diabetes (Ozempic, Trulicity)
- · Respiratory (Dupixent)



## Washington

Drugs under review:

- · Immunology (Enbrel, Humira)
- Oncology (Xtandi, Cabometyx)



Oregon

## Drugs under review:

- Migraine (Ajovy, Emgality, Nurtec, Ubrelvy)
- · Immunology (Cosentyx)
- · Anticoagulants (Eliquis, Xarelto)
- Diabetes (Jardiance, Mounjaro, Ozempic, Rybelsus, Trulicity, Insulin products)
- · Neurology (Vraylar)
- · Cardiovascular (Entresto)
- · Respiratory (Trelegy)
- · Gastrointestinal (Creon)

# to take effect in 2027. The Enbrel UPL in Colorado was based on the Medicare MFP.

After this first UPL-setting, further action from other states is likely

On October 3, 2025, the Colorado PDAB set the first UPL for Enbrel at \$600 a syringe





Maryland

- Drugs deemed "unaffordable" (Cosentyx and Stelara in Colorado and Farxiga and Jardiance in Maryland) are likely to have UPLs set.
- Drugs that have been selected for IRA MDPNP (Jardiance, Xarelto, Farxiga, Entresto, Stelara, Ozempic, Trelegy, Xtandi, Vraylar) are likely to be selected for affordability review.

Sources: "Prescription Drug Affordability Boards," The Partnership for Safer Medicines, https://www.safemedicines.org/2024/08/pdabs.html; "State board determines two Type 2 diabetes drugs may be unaffordable," Maryland Matters, https://marylandmatters.org/2025/07/29/state-board-determines-two-type-2-diabetes-drugs-may-be-un-affordable/#:-:text=1-,State%20board%20determines%20twc%20Type%202%20diabetes%20drugs%20may%20be;really%20big%20deal,%E2%80%9D%3C/; "Policy Blog: Colorado PDAB Sets First Upper Payment Limit," Colorado Bioscience Association, https://cobioscience.org/policy-blog-colorado-pdab-sets-first-upper-payment-limit/#:--text=10/07/2025-,On%200ctober%203%2C%20despite%20hearing%20testimony%20from%20a%20variety%20of,six%20months%20after%20adoption%20date.%E2%80%9D

